Home Hippuric Acid as a Modifier of Calcium Oxalate Crystallisation
Article
Licensed
Unlicensed Requires Authentication

Hippuric Acid as a Modifier of Calcium Oxalate Crystallisation

  • Norbert Laube , Brigitte Jansen , Anke Schneider , Hans-Jürgen Steffes and Albrecht Hesse
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 39 Issue 3

Abstract

Hippuric acid (HA) originating from the conjugation of benzoic acid with glycine is a physiological component of human urine. Findings suggest that HA inhibits calcium oxalate (CaOx) growth and considerably enhances the CaOx solubility in artificial urine. Thus, it is assumed that HA is a major modifier of CaOx formation. However, only a slight CaOx growth inhibition of 1–8 % was also reported. These values were also derived from artificial urine. The key mechanism, which led HA to be of interest in urolithiasis research is the fact that in presence of Ca2+ ions HA can form a hippurate complex. By forming such a complex, Ca2+ concentration in urine decreases, and as a consequence, CaOx formation is inhibited.

This study was performed in order to clarify the role of HA in native and artificial urine. Biochemical analyses to calculate the relative CaOx supersaturations and crystallisation experiments using an in-line laser probe were examined. BONN Risk Indices indicating the risk of CaOx crystallisation were calculated from the results of the crystallisation experiments.

The results obtained from artificial as well as from native urines showed that HA has no significant effects on CaOx formation. We suggest that HA plays only a minor role as a crystallisation modifier in human urine.

:
Published Online: 2005-06-01
Published in Print: 2001-04-09

Copyright © 2001 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. Autoantibodies Associated with Rheumatic Diseases
  2. Simultaneous Detection of Multiple Proteins with an Array-Based Enzyme-Linked Immunosorbent Assay (ELISA) and Enhanced Chemiluminescence (ECL)
  3. Hippuric Acid Test Using 13C-Labelling and NMR Spectroscopy
  4. Hippuric Acid as a Modifier of Calcium Oxalate Crystallisation
  5. Excretion of Sweat and Urine Pyridinoline Crosslinks in Healthy Controls and Subjects with Established Metabolic Bone Disease
  6. Hyperhomocysteinemia and Changed Plasma Thiol Redox Status in Chronic Obstructive Pulmonary Disease
  7. Biochemical Evaluation of Oxidative Stress during Exercise in Patients with Coronary Heart Disease
  8. Prognostic Significance of the Presence of Erythroblasts in Blood after Cardiothoracic Surgery
  9. Exploratory Biochemical Data Analysis: a Comparison of Two Sample Means and Diagnostic Displays
  10. Standardization of Laboratory Data and Establishment of Reference Intervals in the Fukuoka Prefecture: A Japanese Perspective
  11. Calibration, Specificity and Trueness of a Postheparin Plasma Lipoprotein Lipase Assay
  12. Analytical Performance of a Direct Assay for LDL-Cholesterol
  13. Genotyping Method for Point Mutation Detection in the Endothelial Nitric Oxide Synthase Exon 7 Using Fluorescent Probes. Clinical Validation in Systemic Sclerosis Patients
  14. IFCC Reference Measurement Procedure for Substance Concentration Determination of Total Carbon Dioxide in Blood, Plasma or Serum
  15. Joshua Lederberg (Editor-in-Chief): Encyclopedia of Microbiology, 2nd Edition, Vol 1-4
Downloaded on 14.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2001.034/html
Scroll to top button